Why the study?
Do baseline aldosterone concentration and mineralocorticoid receptor genotype predict potassium level elevation in heart failure patients starting spironolactone?
Do baseline aldosterone concentration and mineralocorticoid receptor genotype predict potassium level elevation in heart failure patients starting spironolactone?
Elevated baseline aldosterone levels (>150 pg/ml) and the NR3C2 215G allele strongly predict significant potassium elevation in heart failure patients starting spironolactone.
Should not yet guide spironolactone use in heart failure; leaves open whether aldosterone or NR3C2 testing improves safety.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Cavallari et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: